UNITED LAB (03933): UBT48128 tablets (overweight or obesity) receive implied approval for clinical trial of new drug in China

date
21:57 19/11/2026
avatar
GMT Eight
United Lab (03933) announced that UBT48128 tablets, a Class 1 innovative drug independently developed by its wholly-owned subsidiary United Biotechnology (Zhuhai Hengqin) Co., Ltd., have received implied approval from China's National Medical Products Administration for a new drug clinical trial for the indication of overweight or obesity, with acceptance numbers CXHL2601252, CXHL2601253, and CXHL2601254.
UNITED LAB (03933) announces that UBT48128 tablets, a Class 1 innovative drug independently developed by the company's wholly-owned subsidiary United Biotechnology (Zhuhai Hengqin) Co., Ltd., have received implied approval from China's National Medical Products Administration for a new drug clinical trial for the indication of overweight or obesity, with acceptance numbers CXHL2601252, CXHL2601253 and CXHL2601254. UBT48128 tablets are a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that, through multiple mechanisms including promoting insulin secretion, controlling appetite and regulating energy metabolism, can lower blood glucose and reduce body weight with a once-daily oral dose, helping to improve patient compliance. Preclinical studies in various animal models show that UBT48128 can significantly reduce body weight, with weight-loss effects superior to those of comparator formulations in the trials. The product is expected to demonstrate good therapeutic potential and provide a new treatment option for patients with overweight or obesity. UBT48128 tablets received new drug clinical trial approval from the U.S. Food and Drug Administration ("FDA") on August 11, 2026. In the future, the company will continue to be committed to the research and development of new products, with a focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, deepening its presence in the field of chronic disease treatment, and serving clinical needs and benefiting patients with higher-quality products and a more comprehensive pipeline, which is expected to create greater returns for the company and its shareholders.